Showing results (81-90 of 115) with videos related to

Sort By:
Pageof 12
Expert Opinion on Drug Metabolism & Toxicology|March 19, 2019
Pharmacokinetic and pharmacodynamic considerations in the treatment of the elderly patient with hypertensionL E J Peeters, M P Kester, L Feyz, et al.
Transplantation|June 28, 2003
The superior results of living-donor renal transplantation are not completely caused by selection or short cold ischemia time: a single-center, multivariate analysisJ I Roodnat, I C van Riemsdijk, P G H Mulder, et al.
Transplantation|December 10, 1999
Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipientsP J Gregoor, R G de Sévaux, R J Hené, et al.
Breast Cancer Research and Treatment|April 17, 2023
Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancerE T D Souwer, A Sanchez-Spitman, D J A R Moes, et al.
Transplantation|August 5, 2000
Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reducedN M van Besouw, B J van der Mast, P de Kuiper, et al.
BMC Infectious Diseases|January 19, 2020
The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trialA Abdulla, T M J Ewoldt, N G M Hunfeld, et al.
Pediatric Blood & Cancer|February 17, 2017
Drug-drug interactions in pediatric oncology patientsT E Balk, I H van der Sijs, T van Gelder, et al.
European Journal of Clinical Pharmacology|July 7, 2017
Population pharmacokinetics of haloperidol in terminally ill adult patientsL G Franken, R A A Mathot, A D Masman, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|September 1, 2004
The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapyD A Hesselink, T van Dam, H J Metselaar, et al.
Transplantation|September 26, 2001
Pretransplant donor-specific helper T cell reactivity as a tool for tailoring the individual need for immunosuppressionB J van der Mast, N M van Besouw, P de Kuiper, et al.
Pageof 12